The nitric oxide system plays a significant role in BPC-157s effects
Its a key player in your bodys energy production, which is why you might feel sluggish when your levels are low
SURMOUNT-MAINTAIN (Horn 2026, 112 weeks): continued top dose -21.9% vs 5 mg step-down -16.6% vs placebo -9.9%, rescue therapy 8/25/67%: Aronne JAMA 2024
While they are frequently mentioned together, they differ significantly in origin, structure, and scientific focus
We know B12 deficiency causes symptoms that overlap with and compound GLP-1 side effects , potentially making patients feel worse than they should on therapy alone
So why, then, would we use Methionine (thought to activate mTOR) in our B12/MIC formulation